Evidence map›Paper›PMID 26438504›Full record

ArticleAntimicrobial agents and chemotherapy2015

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.

Aurélie Barrail-Tran, Corine Vincent, Valérie Furlan, Isabelle Rosa, Eric Rosenthal, Antoine Cheret, Jean-Michel Molina, Anne-Marie Taburet, Lionel Piroth, ANRS HC30 QUADRIH Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aurélie Barrail-TranAP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France Université Paris Sud, INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France aurelie.barrail-tran@bct.aphp.fr.
Corine VincentINSERM SC10-US019, Villejuif, France.
Valérie FurlanAP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France.
Isabelle RosaCentre Hospitalier Intercommunal, Service d'Hépato-Gastro-Entérologie, Créteil, France.
Eric RosenthalCHU de Nice, Hôpital de l'Archet, Service de Médecine Interne, Nice, France.
Antoine CheretCH de Tourcoing Hôpital Gustave Dron, SRU Maladies Infectieuses et du Voyageur, Tourcoing, France.
Jean-Michel MolinaHôpital Saint Louis Université Paris Diderot, Service des Maladies Infectieuses et Tropicales, Paris, France.
Anne-Marie TaburetAP-HP, Hôpital Bicêtre, Pharmacie Clinique, Le Kremlin Bicêtre, France Université Paris Sud, INSERM UMR 1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France.
Lionel PirothInfectious Diseases Department, Centre Hospitalo-Universitaire, and UMR 1347, Université de Bourgogne, Dijon, France.
ANRS HC30 QUADRIH Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon-ribavirin and asunaprevir plus daclatasvir. Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy. In addition, concentrations of raltegravir, asunaprevir, and daclatasvir were not affected by liver cirrhosis. These data suggest that in human immunodeficiency virus (HIV)-HCV-coinfected patients, whether cirrhotic or not, asunaprevir and daclatasvir could be administered safely with raltegravir.

Indexed as

AdultAntiviral AgentsCarbamatesCoinfectionDrug Therapy, CombinationFemaleHepacivirusHepatitis C, ChronicHIV-1HIV InfectionsHumansImidazolesInterferon-alphaIsoquinolinesLiverLiver CirrhosisAntiviral AgentsasunaprevirCarbamatesdaclatasvirImidazolesInterferon-alphaIsoquinolinespeginterferon alfa-2aPolyethylene GlycolsPyrrolidinesRaltegravir PotassiumRecombinant ProteinsRibavirinSulfonamidesValine

Identifiers

PMID26438504
PMCPMC4649172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.